RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0
|
作者：
Nakahara, Yoshiro [1 ]
Hosomi, Yukio [1 ]
Yomota, Makiko [1 ]
Okuma, Yusuke [1 ]
Takagi, Yusuke [1 ]
Iguchi, Mari [1 ]
Okamura, Tatsuru [1 ]
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
wild-type EGFR; Erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-034
引用
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [31] RETROSPECTIVE EFFICACY AND SAFETY ANALYSIS OF ERLOTINIB (E), PEMETREXED (P) AND DOCETAXEL (D) IN PREVIOUSLY TREATED NON-SQUAMOUS AND NON-SMALL-CELL LUNG CANCER PATIENTS (NSCLC) WITHOUT EGFR MUTATION
    Takeshita, Jumpei
    Katakami, Nobuyuki
    Nishiyama, Akihiro
    Yoshioka, Hiroshige
    Iwasaku, Masahiro
    Otsuka, Kojiro
    Imamura, Fumio
    Nishino, Kazumi
    Yokota, Soichiro
    Morita, Satoshi
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S489 - S489
  • [32] Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR
    Mitsuoka, Shigeki
    Kawaguchi, Tomoya
    Kubo, Akihito
    Isa, Shun-ichi
    Asai, Kazuhisa
    Uji, Masato
    Watanabe, Tetsuya
    Sawa, Kenji
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumura, Tomohiro
    Tanaka, Hidenori
    Matsuura, Kuniomi
    Kimura, Tatsuo
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Hirata, Kazuto
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 193 - 203
  • [33] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
  • [34] Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
    Kim, Seo Yun
    Myung, Jae Kyung
    Kim, Hye-Ryoun
    Na, Im Il
    Koh, Jae Soo
    Baek, Hee Jong
    Kim, Cheol Hyeon
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2019, 82 (01) : 62 - 70
  • [35] Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)
    Otani, Sakiko
    Sasaki, Jiichiro
    Nakahara, Yoshiro
    Fukui, Tomoya
    Igawa, Satoshi
    Naoki, Katsuhiko
    Bessho, Akihiro
    Hosokawa, Shinobu
    Fukamatsu, Nobuaki
    Nakamura, Yukiko
    Kasai, Takashi
    Sugiyama, Tomohide
    Tokito, Takaaki
    Seki, Nobuhiko
    Hamada, Akinobu
    Okamoto, Hiroaki
    Masuda, Noriyuki
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 530 - 536
  • [36] Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)
    Sakiko Otani
    Jiichiro Sasaki
    Yoshiro Nakahara
    Tomoya Fukui
    Satoshi Igawa
    Katsuhiko Naoki
    Akihiro Bessho
    Shinobu Hosokawa
    Nobuaki Fukamatsu
    Yukiko Nakamura
    Takashi Kasai
    Tomohide Sugiyama
    Takaaki Tokito
    Nobuhiko Seki
    Akinobu Hamada
    Hiroaki Okamoto
    Noriyuki Masuda
    Investigational New Drugs, 2021, 39 : 530 - 536
  • [37] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer Cancer
    Minemura H.
    Yokouchi H.
    Azuma K.
    Hirai K.-I.
    Sekine S.
    Oshima K.
    Kanazawa K.
    Tanino Y.
    Inokoshi Y.
    Ishii T.
    Katsuura Y.
    Oishi A.
    Ishida T.
    Munakata M.
    BMC Research Notes, 8 (1)
  • [38] Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition
    Yang-ling Li
    Yi-ni Pan
    Wen-jue Wu
    Shi-ying Mao
    Jiao Sun
    Yi-ming Zhao
    Jing-yin Dong
    Da-yong Zhang
    Jian-ping Pan
    Chong Zhang
    Neng-ming Lin
    Medical Oncology, 2016, 33
  • [39] Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition
    Li, Yang-ling
    Pan, Yi-ni
    Wu, Wen-jue
    Mao, Shi-ying
    Sun, Jiao
    Zhao, Yi-ming
    Dong, Jing-yin
    Zhang, Da-yong
    Pan, Jian-ping
    Zhang, Chong
    Lin, Neng-ming
    MEDICAL ONCOLOGY, 2016, 33 (02) : 1 - 9
  • [40] A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma
    Li, Ning
    Ou, Wei
    Yang, Hua
    Liu, Qian-Wen
    Zhang, Song-Liang
    Wang, Bao-Xiao
    Wang, Si-Yu
    CANCER, 2014, 120 (09) : 1379 - 1386
12345